Safety and efficacy of endovascular patent foramen ovale closure: the first results of a Russian multicenter study

Patent foramen ovale (PFO) is detectable in more than 25% of the adult population and is generally clinically insignificant. However, it can be a cause of paradoxical embolism in some cases. Randomized trials indicate that endovascular PFO closure in patients with a history of cryptogenic stroke is an effective method for the secondary prevention of catastrophic brain damage.

Objective: to study the safety and efficiency of endovascular PFO closure in young patients with a history of cryptogenic stroke.

Patients and methods. Sixty-two patients, including (22 males and 40 females) women, underwent percutaneous PFO closure in May 2018 to March 2020. The patients' mean age was 37.4±7.6 years. The inclusion criteria were a prior cryptogenic ischemic stroke lasting less than 12 months and PFO with a high risk for paradoxical embolism (PFO concurrent with atrial septal aneurysm or hypermobility; PFO, ≥2 mm size; the presence of the Chiari network and/or the Eustachian valve).

Results and discussion. The technical success of the operation was achieved in all cases. In 50 (80.6%) patients, the right chamber of the heart was completely isolated from the left one in the first 3 months. During the first year, the atria were also completely isolated in 10 (16.1%) patients. A left-to-right shunt persisted in 2 (3.2%) patents 12 months later. Two patients were found to have main procedural complications: one had perioperative atrial fibrillation and the other had pseudoaneurysm formation at the puncture site.

Conclusion. Endovascular PFO closure is a safe and effective operation for the secondary prevention of recurrent ischemic stroke. In our study, blood shunting through the PFO was stopped in 96.6% of patients at less than 6 months after surgery, which suggests that there is a rapid and effective reduction in the risk of paradoxical embolism.

1. Klochikhina OA, Stakhovskaya LV, Polunina EA, et al. Epidemiology and prognosis of the level of morbidity and mortality from stroke in different age groups according to the territorial-population register. Zhurnal nevrologii i psikhiatrii im. C.S. Korsakova. 2019;119(8 iss. 2):5-12. doi: 10.17116/jnevro20191190825 (In Russ.).

2. Giblett JP, Abdul-Samad O, Shapiro LM, et al. Patent foramen ovale closure in 2019. Interv Cardiol. 2019 Feb;14(1):34-41. doi: 10.15420/icr.2018.33.2

3. Kulesh AA, Drobakha VE, Shestakov VV. Cryptogenic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):14- 21. doi: 10.14412/2074-2711-2019-4-14-21 (In Russ.).

4. Kalashnikova LA, Dobrynina LA. Ischemic stroke in young age. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(8):3-12 (In Russ.).

5. Kalashnikova LA, Dobrynina LA, Chechetkin AO, et al. Cerebral circulation disorders during dissection of the internal carotid and vertebral arteries. Diagnostic algorithm. Atmosfera. Nervnyye bolezni. 2016;(2):10- 5 (In Russ.).

6. Fonyakin AV, Suslina ZA, Geraskina LA. Kardiologicheskaya diagnostika pri ishemicheskom insul'te [Cardiological diagnostics in ischemic stroke]. St. Petersburg; 2005 (In Russ.).

7. Piradov MA, Tanashyan MM, Maksimova MYu, editors. Insul't: sovremennyye tekhnologii diagnostiki i lecheniya [Stroke: modern technologies for diagnosis and treatment]. 3rd ed. Moscow: MEDpress-inform; 2018. 360 p. ISBN 978-5-00030-622-2. doi: 10.24421/MP.2018.18.15909 (In Russ.).

8. Calvert PA, Rana BS, Kydd AC, Shapiro LM. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol. 2011 Mar;8(3):148-60. doi: 10.1038/nrcardio.2010.224. Epub 2011 Feb 1.

9. Mekhryakov SA, Kulesh AA, Pokalenko EA, et al. The paradoxical embolism phenomenon in patients with embolic cryptogenic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(1):13-21. doi: 10.14412/2074-2711-2020-1-13-21 (In Russ.).

10. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012 Mar 15;366(11):991-9. doi: 10.1056/NEJMoa1009639

11. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013 Mar 21;368(12):1083-91. doi: 10.1056/NEJMoa1211716

12. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013 Mar 21;368(12):1092-100. doi: 10.1056/NEJMoa1301440

13. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017 Sep 14;377(11):1022-32. doi: 10.1056/NEJMoa1610057

14. Sondergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017 Sep 14;377(11):1033-42. doi: 10.1056/NEJMoa1707404

15. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017 Sep 14;377(11):1011-21. doi: 10.1056/NEJMoa1705915

16. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018 May 22;71(20):2335-42. doi: 10.1016/j.jacc.2018.02.046. Epub 2018 Mar 12.

17. Ahmad Y, Howard JP, Arnold A, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart J. 2018 May 7;39(18):1638-49. doi: 10.1093/eurheartj/ehy121

18. Nasir UB, Qureshi WT, Jogu H, et al. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke. Cardiovasc Revasc Med. 2019 Mar;20(3):187-93. doi: 10.1016/j.carrev.2018.06.001. Epub 2018 Jun 13.

19. Pristipino C, Sievert H, D'Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019 Oct 7;40(38):3182- 95. doi: 10.1093/eurheartj/ehy649

20. Kulesh AA, Ognerubov DV, Mekhryakov SA, et al. Patent foramen ovale-related stroke: diagnostic approaches and the possibility of endovascular prophylaxis (clinical cases and literature review). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):72-8. doi: 10.14412/2074-2711-2020-2-72-78 (In Russ.).

21. Jauss M, Zanette E. Detection of right-toleft shunt with ultrasound contrast agent and transcranial Doppler sonography. Cerebrovasc Dis. Nov-Dec 2000;10(6):490-6. doi: 10.1159/000016119

22. Saidova MA. Transesophageal echocardiography: indications, technique. Bolezni serdtsa i sosudov. 2007;(4):73-8 (In Russ.).

23. Kulesh AA, Syromyatnikova LI, Drobakha VE, et al. Kriptogennyy insul't: Rukovodstvo [Cryptogenic stroke: Manual]. Moscow: GEOTAR-Media; 2020. 128 p. (In Russ.).

24. Kent DM, Dahabreh IJ, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol. 2016 Mar 1;67(8):907-17. doi: 10.1016/j.jacc.2015.12.023

25. Kent DM, Dahabreh IJ, Ruthazer R, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. 2015 Sep 14;36(35):2381-9. doi: 10.1093/eurheartj/ehv252. Epub 2015 Jul 3.